Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Insmed Inc. A complete text table follows the diagram.
The new bronchiectasis medicine transformed a one-product rare-disease company while ARIKAYCE remained its international commercial anchor.
Swipe to explore
Every Sankey value reproduces the filing's product-by-geography revenue table. The seven-month framing measures from the August 2025 U.S. approval to the March 2026 quarter-end; it does not imply seven full months of recognized sales or international launch activity.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Insmed commercial portfolio | 1 | $306M | $306.0M quarterly product revenue |
| BRINSUPRI | 2 | $208M | 68% of product revenue |
| ARIKAYCE | 2 | $98.1M | Established rare-lung-disease franchise |
| United States | 3 | $270M | 88.3% of product revenue |
| International | 3 | $35.9M | Primarily ARIKAYCE at this stage |
| From | To | Value |
|---|---|---|
| Insmed commercial portfolio | BRINSUPRI | $208M |
| Insmed commercial portfolio | ARIKAYCE | $98.1M |
| BRINSUPRI | United States | $207M |
| BRINSUPRI | International | $0.7 |
| ARIKAYCE | United States | $62.9M |
| ARIKAYCE | International | $35.2M |